Tebapivat
AG946-C-003
Phase 2 small_molecule active
Quick answer
Tebapivat for Sickle Cell Disease is a Phase 2 program (small_molecule) at Agios Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Agios Netherlands B.V.
- Indication
- Sickle Cell Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active